DENTSPLY SIRONA (XRAY) Getting Somewhat Favorable Press Coverage, Analysis Finds
Media stories about DENTSPLY SIRONA (NASDAQ:XRAY) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DENTSPLY SIRONA earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news stories about the medical instruments supplier an impact score of 46.9876824492083 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media headlines that may have effected Accern Sentiment’s analysis:
- XRAY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of … (businesswire.com)
- Dentsply Sirona chairman, CEO and COO all resign (finance.yahoo.com)
- A Kick in the Teeth from Dentsply (finance.yahoo.com)
- INVESTOR ALERT: Investigation of Dentsply Sirona Announced by Holzer & Holzer (finance.yahoo.com)
- XRAY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Dentsply Sirona, Inc. (finance.yahoo.com)
XRAY has been the subject of a number of recent analyst reports. UBS AG reaffirmed a “neutral” rating and set a $59.00 price target (down from $62.00) on shares of DENTSPLY SIRONA in a report on Thursday, August 10th. BidaskClub lowered shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Jefferies Group LLC lowered their price target on shares of DENTSPLY SIRONA from $72.00 to $66.00 and set a “buy” rating for the company in a report on Wednesday, August 23rd. Zacks Investment Research lowered shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $66.00 price target (down from $70.00) on shares of DENTSPLY SIRONA in a report on Thursday, August 10th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $65.67.
DENTSPLY SIRONA (XRAY) opened at 57.21 on Thursday. The company’s market capitalization is $13.13 billion. DENTSPLY SIRONA has a 1-year low of $52.54 and a 1-year high of $65.68. The firm’s 50-day moving average is $56.90 and its 200-day moving average is $61.30.
DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.65. DENTSPLY SIRONA had a negative net margin of 20.57% and a positive return on equity of 7.24%. The business had revenue of $992.70 million for the quarter, compared to analyst estimates of $1 billion. During the same quarter in the previous year, the firm posted $0.76 earnings per share. DENTSPLY SIRONA’s revenue was down 2.9% compared to the same quarter last year. Equities research analysts predict that DENTSPLY SIRONA will post $2.68 EPS for the current year.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.
Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.